A team of former Pharmacyclics Inc. executives hope to raise $115 million for their cancer-fighting company in the Bay Area's first life sciences IPO filing of 2016.
Corvus Pharmaceuticals Inc. of Burlingame expects to use the cash to take its lead drug through clinical trials, push another drug through preclinical development and fund other early-stage research and development, it said Monday in a filing with the Securities and Exchange Commission.
Corvus Pharmaceuticals Inc. of Burlingame expects to use the cash to take its lead drug through clinical trials, push another drug through preclinical development and fund other early-stage research and development, it said Monday in a filing with the Securities and Exchange Commission.
